Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

By M. Ekstedt, H. Hagström, P. Nasr, M. Fredrikson, P. Stål, S. Kechagias, R. Hultcrantz. Hepatology, 2015

2,093 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/3e7389bb89eed4ef3573c065345bee1d99faf845

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. G. Targher
2. Z. Younossi
3. Megan H. Bair-Merritt
4. Christopher D. Byrne
5. Q. Anstee
6. A. Lonardo
7. Asociacion Latinoamericana para el Estudio del Higado
8. A. Sanyal

In Epidemiology

1. Z. Younossi
2. G. Targher
3. Megan H. Bair-Merritt
4. Christopher D. Byrne
5. Q. Anstee
6. A. Sanyal
7. A. Lonardo
8. S. Harrison

In Hepatology

1. Z. Younossi
2. Megan H. Bair-Merritt
3. G. Targher
4. A. Sanyal
5. Christopher D. Byrne
6. A. Lonardo
7. Q. Anstee
8. Asociacion Latinoamericana para el Estudio del Higado

Citations in the corpus

• Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease (2017, neutral): “(Angulo et al., 2015; Dulai et al., 2017; Ekstedt et al., 2015; Younossi et al., 2015) Early identification of the presence of advanced fibrosis using non-invasive modalities is a major unmet need in the field.”
• The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent (2016, neutral): “Most importantly the MBOAT7 variant was independently associated with development of fibrosis (Table 2 and Figure 2), which represents the major determinant of the prognosis of patients with NAFLD 39, 40 .”
• Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. (2016, background): “594 Journal of Hepatology 201 ultrasonography or computed tomography) or by histology in a single study [33].”
• Epidemiology of metabolic dysfunction-associated steatotic liver disease (2024, background): “[47-49] Type 2 Diabetes (T2D) T2D is expected to impact nearly 600 million people globally by 2035 but prevalence rates vary around the globe.”
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016, background): “These 2 latter conditions carry the heaviest toll in terms of mortality, the leading cause of death being from cardiovascular events.(3,7,8) Peroxisome proliferator activated receptors (PPARs) are nuclear receptors playing key roles in cellular processes regulating metabolic homeostasis, immune-infl”